biosimilars
Samsung completes hat-trick of big biosimilar approvals
August 25, 2017Medical Communications, Sales and Marketing Biogen, Samsung Bioepis, biosimilars, biotech, drugs, pharma, pharmaceutical
Samsung Bioepis has announced that it, alongside its partner Biogen, has secured European Commission approval for its biosimilar version of …
Novartis CEO reasserts 2018 growth expectations, discusses Alcon and Sandoz future
July 18, 2017Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, biosimilars, biotech, healthcare, joe jimenez, leukaemia, pharma, pharmaceuticals
Novartis has reiterated its expectation of sales growth beginning in 2018, as well as a positive outlook for its Alcon …
Problematic facility inspection puts Biocon’s biosimilar EU approvals on hold
July 10, 2017Manufacturing and Production, Sales and Marketing Biocon, India, biosimilars
Indian firm Biocon has been hit by regulator criticism which has forced its European biosimilar programme on hold following a …
New biosimilar guidelines launched in the EU
June 1, 2017Medical Communications, Research and Development, Sales and Marketing EMA, biosimilars
A joint effort by the EMA and the European Commission has seen the publication of a biosimilar information guide for …
WHO aims to increase uptake of biosimilars in poorer countries
May 4, 2017Medical Communications, Research and Development Cancer, Roche, WHO, biosimilars
The WHO has announced that it will launch a project to prequalify biosimilar medicines for the treatment of certain cancers. …
Patient engagement is key to building a biosimilar market
March 10, 2017Medical Communications Clarivate analytics, biosimilars
There’s a whole lot of explaining to do before many U.S. patients and doctors will feel comfortable with biosimilars in …
Amgen accuses biosimilar producer of ‘massive conspiracy’
March 9, 2017Medical Communications Amgen, Coherus, Neulasta, biosimilars
Amgen has filed a lawsuit in a Californian state court against Coherus Biosciences, suggesting that Coherus had stolen trade secrets. …
Seven pharma trends for 2017
December 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing M&A, MA, biosimilars, collaborations, digital pharma, emerging markets, patient centricity, pharma, pricing
What will be the key industry trends in 2017?Industry uncertaintyPerhaps the biggest hallmark of 2016-going-into-2017 is the sense of hesitation …
Biosimilars and Generics: A no-brainer for treatment?
November 28, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biosimilars, generics
The industry is poised on the potential widespread adoption of many revolutionary technologies; foremost among them are biosimilars and generics, …
J&J loses Remicade patent fight, pledges to continue fight against biosimilars
August 18, 2016Research and Development, Sales and Marketing Johnson and Johnson, Remicade, biosimilar, biosimilars, infliximab, patent
Johnson and Johnson has announced that it has lost in a patent dispute between biosimilar makers Celltrion and Hospira, relating …
Amgen agrees deal to commercialise biosimilars in Japan with Daiichi Sankyo
July 14, 2016Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Daiichi Sankyo, Japan, biosimilars
Amgen (NASDAQ: AMGN) has agreed a deal with Daiichi Sankyo (TSE: 4568) that will see the pair commercialise nine biosimilars …
New data shows Sandoz’s Enbrel biosimilar has equivalent efficacy profile
July 7, 2016Research and Development, Sales and Marketing Amgen, EMA, Enbrel, FDA, Novartis, Sandoz, biosimilars
Sandoz has announced new data confirming the equivalent safety and efficacy profile of their biosimilar version of Enbrel (etanercept) in …
Novartis aims to launch five major global biosimilars by 2020
June 21, 2016Manufacturing and Production, Research and Development 2020, Novartis, Sandoz, biosimilars
Novartis (VTX: NOVN) has announced plans to triple its biosimilar portfolio by 2020, with the launch of five major biosimilar …
Sandoz biosimilars as safe and efficacious as originators, says early trials data
June 9, 2016Research and Development Enbrel, MabThera, Novartis, Sandoz, biosimilars, etanercept, rituximab
Sandoz, a division of Novartis, has presented data at the Annual European Congress of Rheumatology (EULAR 2016) demonstrating the safety …
New data on biosimilars of the big three anti-TNF drugs presented at EULAR 2016
June 8, 2016Research and Development, Sales and Marketing Benepali, Biogen, Enbrel, Flixabi, Humira, Remicade, Samsung Bioepis, biosimilars, eular 2016, sb5
Samsung Bioepis has presented data at EULAR 2016 on three biosimilars of the highly selling anti-TNF drugs Remicade (infliximab), Enbrel …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
